—
## Definition
Healthcare Common Procedure Coding System code J9274 is a Level II National Code used for billing and reimbursement purposes within the United States healthcare system. Specifically, this code refers to the injectable drug “enfortumab vedotin-ejfv,” a monoclonal antibody used in the treatment of specific types of urothelial cancer. The description associated with this code indicates the billing is per 0.25 milligrams of the drug administered.
Enfortumab vedotin-ejfv is an antibody-drug conjugate that carries a cytotoxic agent directly to cancer cells, minimizing damage to surrounding healthy tissue. This precision mechanism makes it an innovative option for patients who have not responded adequately to other therapies. The code J9274 facilitates effective tracking, utilization, and billing for this specialty oncology medication.
This drug is often utilized in advanced or metastatic urothelial carcinoma, particularly for patients previously treated with immune checkpoint inhibitors and chemotherapy. As such, J9274 caters specifically to a narrowly defined patient group, underscoring the vital role of precision billing in oncology care.
—
## Clinical Context
The clinical application of enfortumab vedotin-ejfv is predominantly within oncology and concerns patients with carcinoma of the urothelium who have exhausted standard treatments. Urothelial carcinoma primarily affects the bladder but may also involve the upper urinary tract. The drug’s targeted mechanism addresses disease progression in advanced stages of the condition.
Treatment is typically supervised exclusively by oncologists or other specialists in cancer care. It involves outpatient infusion, requiring careful preparation and administration in a controlled setting. Providers are responsible for precise dosing calculations based on patient-specific factors such as body weight and clinical condition.
The drug associated with J9274 is regarded as a second-line or later therapy, signaling its use in cases where other therapies have failed. As side effects can be significant, including peripheral neuropathy and skin reactions, it is often prescribed with a comprehensive risk evaluation.
—
## Common Modifiers
Although J9274 is a drug-specific code, healthcare providers may utilize modifiers to reflect nuances in billing scenarios. The modifier “JW” is commonly appended to denote the unused portion of a single-use vial of enfortumab vedotin-ejfv, ensuring accurate billing and accountability for discarded medication.
Another frequently employed modifier is “JA,” which designates that the drug has been administered intravenously in an outpatient hospital setting. This modifier ensures clarity regarding the site of service, facilitating accurate reimbursement in different clinical contexts.
Providers may also use geographic modifiers when billing under certain payer contracts tied to regional reimbursement rates. These modifiers ensure compliance with payer-specific requirements while adhering to the fair market value of the services rendered.
—
## Documentation Requirements
When coding J9274, documentation must be thorough, encompassing both the clinical justification for enfortumab vedotin-ejfv and the specifics of its administration. The patient’s medical record should indicate a history of prior therapies and the need for this advanced treatment. Detailed notes regarding diagnosis codes, weight-based dosing calculations, and infusion specifics are essential.
Physicians must clearly specify the number of units billed, as J9274 corresponds to increments of 0.25 milligrams. Exact dosage calculations should align with the prescription and pharmacy-prepared quantity, particularly when partial dosage vials are utilized.
Additionally, documentation should address any adverse reactions or treatment deviations. This level of detail is crucial for ensuring the claim withstands scrutiny from auditors or payers and complies with standard medical billing practices.
—
## Common Denial Reasons
Claims involving J9274 may be denied for various reasons, often relating to insufficient documentation or eligibility criteria. One common cause is the failure to provide comprehensive medical records supporting the use of enfortumab vedotin-ejfv, particularly in cases where prior therapies are not documented.
Billing errors, such as incorrect quantity or missing modifiers like “JW” for wasted medication, can also result in denials. Payers have stringent guidelines for calculating the appropriate number of units, and discrepancies can trigger rejections or payment delays.
Another frequent denial issue involves prior authorization lapses. As enfortumab vedotin-ejfv is a high-cost medication, most insurers require pre-approval before treatment, and failure to meet these conditions often leads to nonpayment.
—
## Special Considerations for Commercial Insurers
Commercial insurers typically impose additional layers of scrutiny for claims involving enfortumab vedotin-ejfv due to its cost and specialized use. Providers are often required to submit extensive preauthorization requests, including proof of prior treatment regimens and the rationale for selecting this drug. Denials are common if the documentation lacks sufficient detail, necessitating careful preparation.
Some insurers may restrict coverage based on their specific medical policies, which may narrowly define the clinical scenarios in which J9274 can be reimbursed. For example, coverage might be limited to advanced urothelial carcinoma meeting certain biomarker criteria or disease severity thresholds.
Additionally, commercial insurers may impose step therapy requirements. Providers must demonstrate that a patient has failed alternative, less expensive treatment options before approving the use of enfortumab vedotin-ejfv. Navigating these requirements often necessitates dedicated staff to ensure compliance.
—
## Similar Codes
A related code within the Healthcare Common Procedure Coding System is J9358, which describes “fam-trastuzumab deruxtecan-nxki,” another antibody-drug conjugate used in oncology. Like J9274, J9358 applies to a highly targeted medication utilized for specific cancer types and billed in incremental doses.
Another similar code is J9173, used to bill for “lorlatinib,” a chemotherapeutic agent indicated for non-small cell lung cancer. Although lorlatinib is a small molecule rather than a monoclonal antibody, its advanced therapeutic profile parallels enfortumab vedotin-ejfv in terms of complexity and cost considerations.
J9264, which codes for “paclitaxel infusion,” serves as a broader chemotherapy-related comparator to J9274. While paclitaxel is a more generalized agent, it represents a commonly administered alternative for cancer patients, particularly in earlier treatment stages.
—